Cardiovasculaire Geneeskunde.nl

NOACs RWE

Overzicht van studies naar ervaringen met non-VKA orale anticoagulantia (NOACs) bij patiënten met atriumfibrilleren in de dagelijkse klinische praktijk (‘real world evidence’). We zullen dit overzicht wanneer relevant blijven aanvullen.

Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish nationwide cohort

5 dec. 2019

Nielsen PB, Larsen TB, Skjøth F, et al. Eur Heart J Cardiovasc Pharmacother. 2019, doi: 10.1093/ehjcvp/pvz070

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

22 juli 2019

De Caterina R, Kelly P, Monteiro P et al. BMC Cardiovascular Disorders 2019;19:165

Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity ScoreeMatched Cohort Study

2 juli 2019

Russo V, Attena E, Mazzone C et al., Clinical Therapeutics 2019

Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation

Graham DJ, Baro E, Zhang R et al.

7 mrt. 2019

Graham DJ, Baro E, Zhang R et al., Am J Med. 2019.

Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation

Själander S, Sjögren V, Renlund H et al.,

22 aug. 2018

Själander S, Sjögren V, Renlund H et al., Thromb Res. 2018 May 17;167:113-118

Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V et al.

22 aug. 2018

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V et al., Am J Cardiol. 2018 Jun 2

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial fibrillation Patients with a Non-Sex-Related CHA2DS2-VASc Score of 1

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

31 juli 2018

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

Global Prospective Safety Analysis of Rivaroxaban

Kirchhof P, Radaideh G, Kim Y-H et al., J Am Coll Cardiol 2018;: 72: 2 DOI: 10.1016/j.jacc.2018.04.058

9 juli 2018

Kirchhof P, Radaideh G, Kim Y-H et al., J Am Coll Cardiol 2018; 72: 2 DOI: 10.1016/j.jacc.2018.04.058

Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation

Andersson NW, Svanström H, Lund M et al., Int J Cardiol. 2018

3 juli 2018

Andersson NW, Svanström H, Lund M et al., Int J Cardiol. 2018

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

Martinez BK, Sood NA, Bunz TJ et al. J Am Heart Assoc. 2018

23 apr. 2018

Martinez BK, Sood NA, Bunz TJ et al. J Am Heart Assoc. 2018

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Shah S, Norby FL, Datta YH et al., Blood advances 2018

4 feb. 2018

Shah S, Norby FL, Datta YH et al., Blood advances 2018

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

Li X, Keshishian A, Hamilton M et al., PLoS ONE 2018

30 jan. 2018

Li X, Keshishian A, Hamilton M et al., PLoS ONE 2018

3' Educatie

Real-life NOAC data; zinloze publicaties om snel te vergeten…?

3' educatie - 4 okt. 2017 - Prof. dr. Menno Huisman / prof. dr. Freek Verheugt

Wat kunnen de antistollingspolikliniek en de huisarts doen voor de AF-patiënt?

3' educatie - 10 mei 2017 - Nijmegen - Dr. Marc Brouwer en Stijn van Vugt

10' Educatie

NOAC’s bij ouderen met polyfarmacie

10' educatie - 6 mrt. 2017 - Radboudumc, Nijmegen - Dr. Marc Brouwer - Radboudumc, Nijmegen

15' Educatie

FOCUS: Plaatsbepaling van real world data bij antistollingbehandeling

15' educatie - 4 sep. 2017 - Nieuwegein - Prof. dr. Jan Tijssen, dr. Michiel Coppens, dr. Ron Pisters